These are solid bargains even in the tech space. Even within the hot technology space, there are still stocks trading at attractive valuations. This includes a few top artificial intelligence (AI) stocks. Let's look at three ready for a bull run. Nvidia While Nvidia (NVDA 3.04%) isn't often mentioned when talking about bargain stocks, a case can certainly be made that the stock is currently trading at a bargain valuation. With a forward price-to-earnings (P/E) ratio of around 25 times based on analyst 2026 consensus, and a forward price/earnings-to-growth (PEG) ratio of under 0.7, Nvidia's stock is downright cheap for a company with its growth. Expand NASDAQ : NVDA Nvidia Today's Change ( -3.04 %) $ -5.64 Current Price $ 179.97 Key Data Points Market Cap $4.5T Day's Range $ 179.57 - $ 186.26 52wk Range $ 86.62 - $ 212.19 Volume 1.9M Avg Vol 181M Gross Margin 70.05 % Dividend Yield 0.02 % Nvidia has established itself as the leader in AI infrastructure, as its graphics processing units (GPUs) are the main chips used to power AI workloads. Meanwhile, its CUDA software platform and networking portfolio have helped create a wide moat. With data center infrastructure spending expected to continue to grow rapidly over the next few years, Nvidia is a bargain tech stock to own. Taiwan Semiconductor Manufacturing Another attractively valued stock in the AI infrastructure space is Taiwan Semiconductor Manufacturing (TSM 1.48%), which is the world's leading manufacturer of advanced chips. Despite the company having a near monopoly on making advanced chips like GPUs, the stock trades at just a forward P/E of 23 times and a PEG of below 0.7 times. Expand NYSE : TSM Taiwan Semiconductor Manufacturing Today's Change ( -1.48 %) $ -5.04 Current Price $ 336.32 Key Data Points Market Cap $1.8T Day's Range $ 334.67 - $ 347.05 52wk Range $ 134.25 - $ 351.33 Volume 209K Avg Vol 13M Gross Margin 59.02 % Dividend Yield 0.90 % The foundry is working closely with its customers to increase it...

The rise of artificial intelligence (AI) has left the stock market with relatively few bargain stocks. Many of the top tech stocks have logged triple-digit gains since the bottom of the bear market of 2022. Fortunately, investors can find potentially lucrative stocks without paying uncomfortably high premiums and hoping the growth will hold up long enough to drive market-beating returns. Such possible opportunities exist today with AT&T (NYSE: T), Qualcomm (NASDAQ: QCOM), and International Business Machines (NYSE: IBM). Let's take a closer look at each. AT&T In the push for AI stocks, investors seem to have forgotten about telcos such as AT&T. Admittedly, investors sold the stock in past years, and the magnitude of missteps with DirecTV and its former segment, which is now part of Warner Bros. Discovery, came to light. However, the new and leaner AT&T has shown signs of improvement, strongly competing with its main rivals, Verizon Communications and T-Mobile, as its networks support increasingly critical cloud and AI functions. Despite the company's almost 1.2 million wireless net adds and around 700,000 fiber net adds for the year, revenue for the first nine months of 2024 was $90 billion, representing a modest drop from year-ago levels. Rising equipment costs also weighed on financials, and the $6.7 billion in net income for the first three quarters of 2024 was a 44% yearly decline. Despite the falling profits, AT&T benefits from growth where it counts, and the stock has continued to rise, despite that news. Also, the 13 price-to-earnings ratio (P/E) could point to some undervaluation, positioning investors to profit from a revamped business on the cutting edge of tech. Qualcomm Qualcomm may be one of the more overlooked companies in the AI chip space. The generative AI push also applies to phones, and Qualcomm has addressed this market demand through its AI-equipped Snapdragon 8 Gen 3 chipset. As the 5G upgrade cycle runs its course, Qualcomm can benefit from a n...

Palantir Stock Jumps After Earnings. How It Won Over Valuation Skeptics. MarketWatch Palantir Earnings, Outlook Beat. How Software Maker Stands Out Amid AI Volatility. Investor's Business Daily Stock Market Today, Feb. 3: Palantir Technologies Surges After Record Revenue Growth and Strong AI Demand The Motley Fool

Key Points BML Capital bought 155,000 shares of CarMax in the fourth quarter. As of quarter-end, the CarMax shares were valued at $5.99 million This new stake places CarMax outside the fund’s top five holdings. These 10 stocks could mint the next wave of millionaires › On February 2, BML Capital Management, LLC disclosed a new position in CarMax (NYSE:KMX), acquiring 155,000 shares in an estimated $5.99 million trade based on quarterly average pricing. What happened According to an SEC filing dated February 2, BML Capital Management disclosed a new position in CarMax (NYSE:KMX), purchasing 155,000 shares during the fourth quarter. The estimated value of the trade was $5.99 million, based on the quarter-end share price. What else to know The new position in CarMax represents 5.18% of BML Capital’s reported 13F assets under management after the filing. Top holdings after the quarter: NASDAQ: ACRS: $42.89 million (38.0% of AUM) NASDAQ: AVIR: $26.74 million (23.7% of AUM) NASDAQ: ORMP: $9.03 million (8.0% of AUM) NASDAQ: TIL: $7.10 million (6.3% of AUM) NASDAQ: PMVP: $6.62 million (5.9% of AUM) As of February 2, CarMax shares were priced at $44.78, down 46.84% over the past year and well underperforming the S&P 500’s roughly 15% gain in the same period. Company overview Metric Value Revenue (TTM) $25.94 billion Net income (TTM) $457.84 million Market capitalization $6.58 billion Price (as of February 2) $44.78 Company snapshot CarMax offers a wide selection of used vehicles, including domestic, imported, luxury, hybrid, and electric models, along with extended protection plans and vehicle repair services. The company operates an integrated retail and wholesale model, generating revenue through used vehicle sales, financing via CarMax Auto Finance, and ancillary services such as reconditioning and auctions. It targets retail consumers seeking used vehicles across the United States, serving a broad customer base through a network of stores and digital channels. CarMax is ...

Hi, it’s Veena Ali-Khan in New York, where I caught up with the CEO of a lobbying specialist about his firm’s recent US listing. Elsewhere today, Musk confirms the SpaceX-xAI merger and activist Elliott digs in at Toyota Industries. Today’s top stories Musk’s SpaceX combines with xAI at $1.25 trillion valuation . GIP teams up with EQT in bid to acquire power firm AES. Elliott intensifies standoff over Toyota Industries buyout. SiTime nears $3 billion deal for Renesas timing unit. How AI has upended private equity’s giant software bet. Lobbyist listing Public Policy Holding Company entered US public markets last week, marking a rare debut for a firm built around government relations and political advisory work—a sector that’s traditionally operated behind closed doors. The listing should serve as a test of investor appetite for lobbying platforms at a time when, according to PPHC’s Chief Executive Officer Stewart Hall, political risk is becoming a permanent fixture in corporate decision-making. “There is no political problem today that isn’t also a reputational problem, and vice versa,” Hall said in an interview. “That shift has become existential for boards.” PPHC raised about $50.8 million in its Nasdaq listing, adding to its existing presence on London’s Alternative Investment Market. The firm controls a portfolio of lobbying and public affairs shops operating in Washington and state capitals, such as Crossroads Strategies—whose lobbyists include former US senators Trent Lott and John Breaux. Last year, it agreed to buy comms firm TrailRunner International and strategic consultancy Pine Cove. Recent clients include TikTok and Visa. Unlike the ad agencies or management consultancies that embraced consolidation and listings, advisory firms in Washington have largely remained fragmented and privately owned. Hall said they’re increasingly moving away from a model centered on proximity to Washington, toward one more focused on political intelligence, strategic communic...

Palantir is the market’s most expensive stock—and investors are starting to see why MSN

据报道，美国政府正准备发布一项通用许可证，允许企业在委内瑞拉开采石油，这是特朗普政府放松制裁、重振该国陷入停滞的能源产业计划的一部分。 知情人士透露，美国财政部最快可能在本周发布该许可证。此举是吸引与美国有关联的企业介入、恢复委内瑞拉原油产量的关键一步。 美国上周已发布另一项通用许可证，允许企业买卖委内瑞拉原油。该许可证涵盖多项下游业务，包括将原油装船、出口、运输和炼制，但前提是由“一家已注册的美国实体”执行。 责任编辑：丁文武

格隆汇2月3日｜据知情人士透露，多家大型住房开发商为100万套“特朗普之家”酝酿计划。

Image source: The Motley Fool. Feb. 3, 2026 at 9 a.m. ET Call participants Chairman and Chief Executive Officer — Robert M. Davis Chief Financial Officer — Caroline A. Litchfield President, Research Labs — Dr. Dean Y. Li Vice President, Investor Relations — Peter Dannenbaum Need a quote from a Motley Fool analyst? Email [email protected] Takeaways Total Revenue -- $16.4 billion, representing a 5% increase, or 4% excluding foreign exchange impact. -- $16.4 billion, representing a 5% increase, or 4% excluding foreign exchange impact. Oncology Sales: Keytruda Family -- $8.4 billion, up 5%, driven by uptake in earlier-stage cancers and demand in metastatic indications. -- $8.4 billion, up 5%, driven by uptake in earlier-stage cancers and demand in metastatic indications. Keytruda QLEX U.S. Launch Sales -- $35 million, with management anticipating greater impact after permanent J code implementation expected in April. -- $35 million, with management anticipating greater impact after permanent J code implementation expected in April. Wellrec Sales -- $220 million, reflecting 37% growth, attributed to U.S. uptake in advanced renal cell carcinoma and international launches. -- $220 million, reflecting 37% growth, attributed to U.S. uptake in advanced renal cell carcinoma and international launches. Gardasil Sales -- $1 billion, down 35% due to lower demand in China and Japan; other international growth was 8%, U.S. sales rose 7% mainly from pricing. -- $1 billion, down 35% due to lower demand in China and Japan; other international growth was 8%, U.S. sales rose 7% mainly from pricing. Pneumococcal Vaccine Cefaxib Sales -- $279 million, supported by both retail and non-retail demand, and stronger U.S. seasonal immunization activity. -- $279 million, supported by both retail and non-retail demand, and stronger U.S. seasonal immunization activity. RSV Product Inflonsia Sales -- $21 million, constrained by low infant immunization rates and high RSV antibody inventory. -- $21 m...

Nvidia (NASDAQ: NVDA) dominates AI infrastructure and generates massive free cash flow, but future returns now depend on flawless execution and sustained growth. I break down what the company must deliver next to drive the stock higher. Stock prices used were the market prices of Jan. 27, 2026. The video was published on Feb. 1, 2026. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Should you buy stock in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $446,319!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,137,827!* Now, it’s worth noting Stock Advisor’s total average return is 932% — a market-crushing outperformance compared to 197% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of February 3, 2026. Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy. Rick Orford is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link, they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Key Points ProShares - Ultra QQQ (NYSEMKT:QLD) charges a slightly higher expense ratio and has much larger assets under management (AUM) than Direxion Daily S&P 500 Bull 3X Shares (NYSEMKT:SPXL). SPXL and QLD have nearly identical five-year drawdowns, but SPXL delivered higher five-year growth for $1,000 invested. QLD concentrates much more heavily in technology and communication services than SPXL, which is broader across the S&P 500. These 10 stocks could mint the next wave of millionaires › Direxion Daily S&P 500 Bull 3X Shares (NYSEMKT:SPXL) and ProShares - Ultra QQQ (NYSEMKT:QLD) both offer leveraged exposure to major U.S. indexes, but QLD charges a marginally higher fee, tracks a tech-heavy portfolio, and manages nearly double the assets under management (AUM). SPXL and QLD are both daily leveraged exchange-traded funds (ETFs) designed for aggressive traders seeking amplified returns from headline U.S. equity indexes. While SPXL targets three times (3x) the daily moves of the S&P 500, QLD seeks two times (2x) the daily performance of the Nasdaq-100, resulting in different sector exposures and risk profiles. Snapshot (cost & size) Metric SPXL QLD Issuer Direxion ProShares Expense ratio 0.93% 0.98% 1-yr return (as of 2026-01-30) 24.6% 27.6% Dividend yield 0.7% 0.2% Beta 3.09 2.34 AUM $5.9 billion $10.7 billion Beta measures price volatility relative to the S&P 500; beta is calculated from five-year weekly returns. The 1-yr return represents total return over the trailing 12 months. QLD comes with a marginally higher expense ratio than SPXL, making SPXL slightly more affordable for cost-conscious traders. QLD also offers a lower dividend yield, so investors seeking income may find SPXL more appealing for its higher payout. Performance & risk comparison Metric SPXL QLD Max drawdown (5 y) -63.84% -63.78% Growth of $1,000 over 5 years $3,127 $2,370 What's inside QLD seeks to deliver twice the daily performance of the Nasdaq-100 Index and has been operating for nearl...

American downhill skier Lindsey Vonn says she has ruptured one of her anterior cruciate ligaments but still hopes to compete at the Winter Olympics in Italy. The 41-year-old was airlifted to hospital in Switzerland on Friday after crashing in the final World Cup race before the Games. The former Olympic champion said her knee feels "stable, strong and is not swollen" and is "very hopeful" she will make the women's downhill event in Cortina on Sunday. "This is obviously not what I hoped for. I have been working really hard to come into these Games in a much different position. "I know what my chances were before the crash and I know that my chances aren't the same as it stands now, but I know there is still a chance. "As long as there is a chance, I'll try. That's where I am."

格隆汇2月3日｜据中国电建消息，2月2日，中国电建党委书记、董事长丁焰章，党委副书记、总经理王小军在总部同清华大学党委书记、中国科学院院士邱勇举行会谈，共同见证双方战略合作协议签署。根据协议，双方将在服务国家重大工程、开展科研攻关、共建科研平台、人才互聘引进、校企协同育人、高质量共建“一带一路”、共建非洲中心等重点领域建立全面合作关系，积极推进资源共享，实现合作共赢、共同发展。

When ChatGPT launched, in November of 2022, it started a race that almost immediately consumed the tech industry. OpenAI didn’t invent the concept of AI, but most of the state-of-the-art technology was confined to research labs at companies and institutions around the world. Then, suddenly, it was everywhere. And better than anyone expected. So many companies decided they needed to catch up as quickly as possible, by any means necessary, or risk losing the battle for maybe the most important technology ever. Verge subscribers, don’t forget you get exclusive access to ad-free Vergecast wherever you get your podcasts. Head here. Not a subscriber? You can sign up here. On this episode of The Vergecast, we talk about one version of that scramble. The Washington Post’s Will Oremus joins the show to talk about the details he and his team uncovered about “Project Panama,” a huge effort inside Anthropic to access and digitize vast quantities of book in order to feed them into large language models. Anthropic’s plan — which included book cutters, piracy websites, and enormous warehouses — sounds a lot like what’s happening at other companies, too. The fight over whether any of it is right, legally or morally, is very much ongoing. After that, Puck’s Julia Alexander joins the show to talk Netflix and the movies. As it continues to try to buy Warner Bros., Netflix is saying all the right things about movie theaters, big-budget films, and generally caring about Hollywood. But of course it is — it’s trying to buy Warner Bros.! Once this all shakes out, can theaters survive in an increasingly Netflix-ified world? Do people even want to see Netflix movies in theaters? And if not, what do we do with these big buildings and their big screens? Luckily we have some ideas. Finally, The Verge’s Jennifer Pattison Tuohy answers a question from the Vergecast Hotline (call 866-VERGE11 or email vergecast@theverge.com!) about Ikea’s new smart buttons and why they don’t seem to work very well....

Alexandros Michailidis/iStock Editorial via Getty Images Pfizer ( PFE ) fell ~5% on Tuesday as Wall Street analysts assessed mid-stage data the company posted for its obesity therapy PF-08653944 ahead of its consensus-beating Q4 2025 results, which indicated a revenue decline for the COVID-19 vaccine maker this year. Citing topline data, the New York-based pharma giant said that its GLP-1 receptor agonist added from its recent $10B acquisition of Metsera (MTSR) generated up to ~12% weight loss in its Phase 2b VESPER-3 study. While the efficacy level of the injectable trailed the established weight loss drugs from Novo Nordisk ( NVO ) and Eli Lilly ( LLY ), its safety profile also raised concerns after as many as 10 patients discontinued the ongoing trial due to adverse events. “While the development for this program is coming along, I think the data today may leave a bit more to be desired from a competitive perspective,” Evercore ISI analyst Umer Raffat wrote with an Outperform rating on PFE. BMO Capital Markets analyst Evan Seigerman noted concerns remaining over “potential benefits from the placebo and study discontinuation rates into the full data.” “Pfizer’s foray into obesity leaves more questions; full data is key,” Bloomberg reported, quoting Seigerman, who rates PFE with an Outperform rating. Meanwhile, JPMorgan’s Chris Schott added that more data are required to evaluate the viability of the company’s obesity therapy, even though its Q4 results exceeded expectations. As for earnings, the company did beat the consensus, as its non-COVID products, such as the Prevnar family of vaccines, the RSV shot Abrysvo, and the blood thinner Eliquis, marketed with Bristol Myers ( BMY ), generated Q4 sales growth operationally. However, revenue from PFE’s COVID-19 products Paxlovid and Comirnaty continued to drop, and the company’s full-year revenue outlook of $59.5B-$62.5B fell short of the $61.01B in the consensus at the mid-point and $62.6B recorded in 2025. According...

After a stretch of underperformance, Nvidia’s stock could come alive after earnings, upcoming industry events and the expected launch of new AI models by companies using its Blackwell chips.

Image source: The Motley Fool. Tuesday, Feb. 3, 2026 at 9 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Carl Hess Chief Financial Officer — Andrew Krasner President, Health, Wealth, and Career — Julie Gebauer President, Risk and Broking — Lucy Clarke Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS Organic Revenue Growth -- 6% in the fourth quarter and 5% for the full year, with mid-single-digit targets reaffirmed. -- 6% in the fourth quarter and 5% for the full year, with mid-single-digit targets reaffirmed. Adjusted Operating Margin -- Expanded by 80 basis points year over year in the fourth quarter to 36.9%, including a 50 basis point tailwind from the TRANZACT divestiture. -- Expanded by 80 basis points year over year in the fourth quarter to 36.9%, including a 50 basis point tailwind from the TRANZACT divestiture. Adjusted Diluted EPS -- $8.12 in the fourth quarter, representing a 13% increase when excluding TRANZACT, and $17.08 for the full year, also up 13% on the same basis. -- $8.12 in the fourth quarter, representing a 13% increase when excluding TRANZACT, and $17.08 for the full year, also up 13% on the same basis. Health, Wealth, and Career Segment -- Delivered 6% organic growth in fourth quarter revenue, 4% for the full year, and operating margin of 44.3% in the quarter, up 240 basis points year over year. -- Delivered 6% organic growth in fourth quarter revenue, 4% for the full year, and operating margin of 44.3% in the quarter, up 240 basis points year over year. Risk and Broking Segment -- Achieved 7% organic growth in the fourth quarter and 6% for the full year, with Corporate Risk and Broking (CRB) delivering 8% quarterly organic growth and 7% annual growth; operating margin improved by 120 basis points to 34.7% in the quarter. -- Achieved 7% organic growth in the fourth quarter and 6% for the full year, with Corporate Risk and Broking (CRB) delivering 8% quarterly organic growth and 7% annual growth; operating margi...

财联社2月3日讯（记者 吴蔚玲） 继股权转让纠纷后， 良品铺子 （603719.SH）控股股东宁波汉意创业投资合伙企业（有限合伙）（下称“宁波汉意”）再添股权变数。因债务逾期，宁波汉意所持的部分公司股份可能被强制执行。 2024年1月，宁波汉意向云南国际信托有限公司（下称“云南信托”）申请了三笔贷款共计3亿元，累计向云南信托质押良品铺子股份5340万股，占公司总股本的13.32%，占其所持公司股份的37.8%。杨红春、杨银芬、张国强为前述债务提供连带责任保证担保。2025年5月，云南信托将该债权全部转让给了国通信托。 截至目前，该债务已逾期，债务本金余额为2.8亿元。国通信托日前依照相关程序向法院申请执行。武汉市东西湖区人民法院向杨红春、杨银芬、张国强等分别出具了执行通知书，三份执行书执行标的合计约2.81亿元，执行费合计48.28万元。 根据执行通知书，宁波汉意及相关被执行人在收到前述通知书后需立即履行相关债权文书所确定的义务，逾期不履行则强制执行。 良品铺子表示，根据执行通知书，宁波汉意持有的部分公司股份存在被强制执行的可能，可能导致宁波汉意持有的公司权益发生变化。 良品铺子还提到，公司与宁波汉意是相互独立的主体，目前该事项未对公司日常经营管理产生直接重大影响，公司生产经营正常，各项业务均仍在有序进行中。 此前，宁波汉意因与广州轻工工贸集团有限公司的股权转让纠纷，其所持有的209.06万股被司法冻结。截至目前，宁波汉意被质押以及司法冻结的股份合计达到7799.06万股，占其所持股份比例的50.89%，占公司总股本的19.45%。

Soybeans are trading with 7 to 9 cent gains on Tuesday AM trade. Futures saw weaker trade on Monday with contracts closing 4 to 5 cents lower in the nearbys. Open interest was down just 225 contracts on Monday. The cmdtyView national average Cash Bean price was 1 3/4 cents lower at $9.96 3/4. Soymeal futures were 20 to 90 cents higher, with Soy Oil futures were down 30 to 37 points at the close. Bean oil is up 138 points this morning. USDA’s FGIS tallied soybean export shipments at 1.31 MMT (48.15 mbu) during the week ending on January 29. That was 1.9% below the week prior but 14.9% above the same week last year. China was the top destination of 740,004 MT, with 137,596 MT headed to Mexico and 121,059 MT to Egypt. Marketing year exports for 2025/26 are 21.99 MMT (808 mbu) since September 1, which is now 35.7% below the same period last year and has closed the gap since early January by nearly 10 percentage points. Don’t Miss a Day: Just prior to midday, President Trump issued a Truth Social post that a call with India’s President Modi went well with the US lowering tariffs on the country from 25% to 18% and India agreeing to buy over $500 billion of US energy, technology, agricultural, coal and other products. India has historically been a top 5 buyer of US bean oil and was the top buyer in 2025. USDA’s monthly Fats & Oils report from Monday afternoon showed a total of 229.84 million bushels of soybeans crushed in December, shy of trade estimates. That was still 4.24% above November and 5.59% larger yr/yr. Marketing year crush since September has totaled 891.58 million bushels, which is up 7.43% from the same period last year. StoneX estimates the Brazilian soybean crop at 181.6 MMT, a 4 MMT increase from their previous projection. The Celeres forecast was up 4.1 MMT to 181.3 MMT. Mar 26 Soybeans closed at $10.60 1/4, down 4 cents, currently up 8 1/4 cents Nearby Cash was $9.96 3/4, down 1 3/4 cents, May 26 Soybeans closed at $10.72 1/2, down 4 1/2 cents, currently...

《科创板日报》2月3日讯（记者 李明明 吴旭光） 近日，天仪空间科技股份有限公司（下称“天仪研究院”）在湖南证监局完成IPO辅导备案，将这家一度被称为航天界“拼多多”的商业卫星企业推向资本市场。 根据辅导备案报告，天仪研究院有望于今年上半年就完成备案流程并正式递交招股书。 作为国内首批商业卫星企业代表，天仪研究院的资本化动作，不仅凸显其在SAR卫星赛道的积累成果，更折射出2026年商业航天行业IPO竞速的白热化态势。 押注SAR赛道 天仪研究院由创始人兼CEO杨峰于2015年5月18日创立，是中国首家运营SAR（合成孔径雷达）遥感卫星的商业航天公司。该公司总部位于长沙高新区，致力于为用户提供极致性价比的SAR星座建设和SAR卫星数据一体化服务。 成立以来，天仪完成约21次太空任务，成功发射包括中国首批商业组网SAR卫星“海丝一号”、“巢湖一号”、“涪城一号”、“神启号01星”及“神启号02星”在内的共37颗卫星， 填补我国商业SAR卫星的空白。公司同时具备业务化InSAR干涉成像能力，可实现对地表毫米级形变监测，为用户提供常态化、高品质及自主可控的商业SAR数据服务。 SAR卫星，是一种主动式微波遥感卫星。与光学卫星依赖太阳光照不同，SAR卫星通过自身发射雷达波并接收回波来成像，具备全天时、全天候的对地观测能力，能够穿透云层和部分植被，在灾害监测、资源勘查、海洋观测等领域具有重要应用价值。 在商业航天的细分赛道中， 不同于传统航天企业的重资产模式，天仪研究院聚焦轻小型SAR卫星的研制与应用，凭借低成本、快部署的特点，在业内有航天界“拼多多”的称号。 他们提出了做轻小型SAR卫星的想法，并成功将卫星重量从传统的几吨减少到几百斤。 杨峰曾表示，使用工业级材料代替宇航级材料是天仪研究院成本下降的关键。他甚至大胆使用了42块钱的消费级摄像头来观察自研卫星的离轨帆能否正常打开。 80后创始人毕业于北京航空航天大学 天仪研究院的IPO征程，离不开创始人杨峰的战略引领。 公开信息显示，杨峰作为公司控股股东、实际控制人，直接和间接控制公司30.15%股权。 2014年末，国务院出台关于创新重点领域投融资机制鼓励社会投资的指导意见，明确鼓励民间资本研制、发射和运营商业遥感卫星。从小就对太空满怀憧憬的杨峰——毕业于北京航空航天大学的“80后”湖南青年，看到了实现梦想的机会。 2015年...

Analysts reset Amazon stock price target before earnings thestreet.com